Thalidomide for the control of severe paraneoplastic pruritus associated with Hodgkin's disease.
A 22-year-old woman with nodular sclerosis type II Hodgkin lymphoma diagnosed in June 2001. She initially underwent chemotherapy with 6 cycles of ABVD (adriamycin, bleomycin, vincristine, dacarbazine) regimen, leading to clinical remission. As it relapsed, she was again treated with 2 different chemotherapy regimens. In November 2003, she underwent bone marrow autotransplantation, but it relapsed after 2 months. After that, she was treated with chemotherapy in monotherapy until November 2005. In December 2005, she was referred to palliative care. Her main symptom was very severe pruritus that interfered with all aspects of her life, making her scratch continuously and interfering in all aspects of her life. She was treated with loratadine, hydroxyzine, prednisolone, paroxetine, mirtazapine, cimetidine, and ondansetron, individually and in various combinations. She also underwent ultraviolet phototherapy. All trials failed and her pruritus remained at level 8 of 10 most of the time. In April 2006, she started on thalidomide, 200 mg at night. The pruritus significantly improved to a level of 3 of 10 but did not disappear completely. She was at last able to sleep properly at night. She remained with a low level of pruritus until her death in July 2008, at the same dose of thalidomide.
Gonçalves
Ferraz
F
Instituto Português de Oncologia, Porto, Portugal. ferrazg@ipoporto.min-saude.pt
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D017809:Fatal Outcome; D005260:Female; D006689:Hodgkin Disease / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D010166:Palliative Care / Q000379:methods*; D010257:Paraneoplastic Syndromes; D011537:Pruritus / Q000188:drug therapy* / Q000209:etiology; D013792:Thalidomide / Q000627:therapeutic use*; D055815:Young Adult
D007166:Immunosuppressive Agents; D013792:Thalidomide